Hologic (NASDAQ:[[ticker:HOLX]]), a Bedford, MA-based provider of women’s healthcare products, says that the FDA has approved two of its “Cervista” tests for detecting human papillomavirus (HPV), a major cause of cervical cancer. One of the tests is intended to identify 14 “high-risk” strains of HPV, according to the firm, and the other test is designed to detect two strains that are linked to 70 percent of cases of cervical cancer in the U.S. Late this morning the firm’s stock had jumped 82 cents per share, or 7.75 percent, to $11.40, on the news.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
